AZ/MSD’s PARP inhibitor shows promise as first-line ovarian ...

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.

AZ's lung cancer drug Tagrisso gets boost from first line OS...

AstraZeneca has announced figures confirming that its Tagrisso extends overall survival in patients with untreated non-small cell lung cancer with certain mutations, compared with older alt

AZ/MSD’s Lynparza sees positive results in prostate cancer

AstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).

AstraZeneca and lung cancer: the pharmaphorum podcast

This episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR (Tumour Drivers and Resistance) Patrick Connor explaining why the

AZ’s Forxiga gets heart claim data on its EU label

Lung cancer’s patient information gap: the pharmaphorum podc...

For episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s the company’s director of oncology advocacy and government affairs, to talk